US2018110854A1PendingUtilityA1

Methods for treating juvenile idiopathic arthritis

60
Assignee: ABBVIE BIOTECHNOLOGY LTDPriority: Jun 11, 2007Filed: Jun 5, 2017Published: Apr 26, 2018
Est. expiryJun 11, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:John R. MedichSusan K. PaulsonPeter A. Noertersheuser
C07K 16/241A61K 2039/505C07K 2317/21A61K 31/519A61K 39/3955A61K 9/0019A61K 31/155
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating juvenile idiopathic arthritis (JIA) in a subject comprising administering a TNFα inhibitor to the subject, wherein the TNFα inhibitor is administered to the subject according to a fixed dosing regimen.

Join the waitlist — get patent alerts

Track US2018110854A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.